Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H26N2O4S |
Molecular Weight | 378.486 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(CC1=CC=CC=C1)NCC(O)C2=CC(NS(C)(=O)=O)=C(O)C=C2
InChI
InChIKey=XJBCFFLVLOPYBV-UHFFFAOYSA-N
InChI=1S/C19H26N2O4S/c1-19(2,12-14-7-5-4-6-8-14)20-13-18(23)15-9-10-17(22)16(11-15)21-26(3,24)25/h4-11,18,20-23H,12-13H2,1-3H3
Molecular Formula | C19H26N2O4S |
Molecular Weight | 378.486 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/4144240Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/39574 | https://www.ncbi.nlm.nih.gov/pubmed/8974046 | https://www.ncbi.nlm.nih.gov/pubmed/16601951 | https://www.ncbi.nlm.nih.gov/pubmed/11325796
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4144240
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/39574 | https://www.ncbi.nlm.nih.gov/pubmed/8974046 | https://www.ncbi.nlm.nih.gov/pubmed/16601951 | https://www.ncbi.nlm.nih.gov/pubmed/11325796
Zinterol (MJ-9184-1) is an beta-adregenrgic agonist demostrated activity toward beta1-3 receptors. Oral zinterol caused a fast-appearing and long-lasting bronchodilator effect in patients with with stable chronic obstructive lung disease, however it seems development of zinterol was discontitued.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8098163 | https://www.ncbi.nlm.nih.gov/pubmed/7862834
Curator's Comment: Zinterol (MJ-9184-1) is CNS active in animals. No human study available.
Originator
Sources: https://www.google.com/patents/US3919424
Curator's Comment: Comer and Roth, 1972 (Mead Johnson & Co)
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11325796 |
|||
Target ID: CHEMBL246 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16601951 |
|||
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
beta-Adrenergic receptor stimulation of L-type Ca2+ channels in rabbit portal vein myocytes involves both alphas and betagamma G protein subunits. | 2001 Feb 15 |
|
Enhanced cardiac L-type calcium current response to beta2-adrenergic stimulation in heart failure. | 2001 Jul |
|
Murine ventricular L-type Ca(2+) current is enhanced by zinterol via beta(1)-adrenoceptors, and is reduced in TG4 mice overexpressing the human beta(2)-adrenoceptor. | 2001 May |
|
Phosphatidylinositol 3-kinase functionally compartmentalizes the concurrent G(s) signaling during beta2-adrenergic stimulation. | 2002 Jul 12 |
|
Multiple signalling pathways involved in beta2-adrenoceptor-mediated glucose uptake in rat skeletal muscle cells. | 2006 Feb |
|
Endurance exercise training attenuates cardiac beta2-adrenoceptor responsiveness and prevents ventricular fibrillation in animals susceptible to sudden death. | 2006 Jun |
|
Tissue functions mediated by beta(3)-adrenoceptors-findings and challenges. | 2010 Aug |
|
The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. | 2010 Jul |
|
A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors. | 2010 Nov 30 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/39574
In double-blind cross-over study including placebo, 0.25 mg and 0.50 mg zinterol (MJ-9184-1) and involving ten patients with stable chronic obstructive lung disease with reversible airways obstruction, MJ-9184-1 caused a fast-appearing and long-lasting bronchodilator effect. The oral intake of 0.50 mg MJ-9184-1, compared to 0.25 mg, caused a more rapid effect and a more pronounced bronchodilation; 0.50 mg MJ-9184-1 also caused some elevation of the pulse rate. The effect was not seen after 0.25 mg MJ-9184-1.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8974046
Zinterol caused positive inotropic and lusitropic effects in the isolated human right atrial appendage with EC50 values of 3 and 2 nM, respectively.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:49:37 GMT 2023
by
admin
on
Fri Dec 15 15:49:37 GMT 2023
|
Record UNII |
7167N7AJJR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Fri Dec 15 15:49:37 GMT 2023 , Edited by admin on Fri Dec 15 15:49:37 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
37990
Created by
admin on Fri Dec 15 15:49:37 GMT 2023 , Edited by admin on Fri Dec 15 15:49:37 GMT 2023
|
PRIMARY | |||
|
CHEMBL1243407
Created by
admin on Fri Dec 15 15:49:37 GMT 2023 , Edited by admin on Fri Dec 15 15:49:37 GMT 2023
|
PRIMARY | |||
|
SUB00165MIG
Created by
admin on Fri Dec 15 15:49:37 GMT 2023 , Edited by admin on Fri Dec 15 15:49:37 GMT 2023
|
PRIMARY | |||
|
ZINTEROL
Created by
admin on Fri Dec 15 15:49:37 GMT 2023 , Edited by admin on Fri Dec 15 15:49:37 GMT 2023
|
PRIMARY | |||
|
37000-20-7
Created by
admin on Fri Dec 15 15:49:37 GMT 2023 , Edited by admin on Fri Dec 15 15:49:37 GMT 2023
|
PRIMARY | |||
|
100000078769
Created by
admin on Fri Dec 15 15:49:37 GMT 2023 , Edited by admin on Fri Dec 15 15:49:37 GMT 2023
|
PRIMARY | |||
|
7167N7AJJR
Created by
admin on Fri Dec 15 15:49:37 GMT 2023 , Edited by admin on Fri Dec 15 15:49:37 GMT 2023
|
PRIMARY | |||
|
C152958
Created by
admin on Fri Dec 15 15:49:37 GMT 2023 , Edited by admin on Fri Dec 15 15:49:37 GMT 2023
|
PRIMARY | |||
|
C002904
Created by
admin on Fri Dec 15 15:49:37 GMT 2023 , Edited by admin on Fri Dec 15 15:49:37 GMT 2023
|
PRIMARY | |||
|
4301
Created by
admin on Fri Dec 15 15:49:37 GMT 2023 , Edited by admin on Fri Dec 15 15:49:37 GMT 2023
|
PRIMARY | |||
|
DTXSID70865845
Created by
admin on Fri Dec 15 15:49:37 GMT 2023 , Edited by admin on Fri Dec 15 15:49:37 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |